Company Description
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States.
The company’s lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy.
It also develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases.
In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid.
The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
| Country | United States |
| Founded | 2013 |
| IPO Date | Jan 26, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 100 |
| CEO | Alexander Cumbo |
Contact Details
Address: 500 Rutherford Avenue, Third Floor Charlestown, Massachusetts 02129 United States | |
| Phone | 617 337 4680 |
| Website | solidbio.com |
Stock Details
| Ticker Symbol | SLDB |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001707502 |
| CUSIP Number | 83422E105 |
| ISIN Number | US83422E2046 |
| Employer ID | 90-0943402 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Ilan Ganot | Co-founder, Strategic Advisor to the Chief Executive Officer and Director |
| Alexander G. Cumbo | President, Chief Executive Officer and Director |
| Ian F. Smith A.C.A., C.P.A. | Executive Chair |
| David Tyronne Howton Jr., J.D. | Chief Operating Officer and Secretary |
| Dr. Gabriel Brooks M.D. | Chief Medical Officer |
| Annie Ganot | Co-Founder and Vice President of Patient Advocacy |
| Kevin Tan C.F.A. | Chief Financial Officer and Treasurer |
| Paul Herzich | Chief Technology Officer |
| Nicole Anderson | Director of Investor Relations and Corporate Communications |
| Allison Bogosian J.D. | Senior Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 11, 2025 | PRE 14A | Other preliminary proxy statements |
| Mar 14, 2025 | EFFECT | Notice of Effectiveness |
| Mar 14, 2025 | EFFECT | Notice of Effectiveness |
| Mar 11, 2025 | UPLOAD | Filing |
| Mar 11, 2025 | UPLOAD | Filing |
| Mar 6, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 6, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 6, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 6, 2025 | 10-K | Annual Report |
| Feb 25, 2025 | SCHEDULE 13G | Filing |